These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35041178)

  • 1. Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis.
    Kuchimanchi M; Bockbrader H; Dolphin N; Epling D; Quinlan L; Chapel S; Penner N
    Neurol Ther; 2022 Mar; 11(1):353-371. PubMed ID: 35041178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate).
    Rousseau FS; Wang L; Sprague TN; Lategan TW; Berkovich RR
    Mult Scler Relat Disord; 2023 Feb; 70():104500. PubMed ID: 36645997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
    Gudesblatt M; Roman C; Singer BA; Schmidt H; Thomas J; Shankar SL; Lyons J; Kapadia S
    Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diroximel fumarate to treat multiple sclerosis.
    Wang Y; Bhargava P
    Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Naismith RT; Wolinsky JS; Wundes A; LaGanke C; Arnold DL; Obradovic D; Freedman MS; Gudesblatt M; Ziemssen T; Kandinov B; Bidollari I; Lopez-Bresnahan M; Nangia N; Rezendes D; Yang L; Chen H; Liu S; Hanna J; Miller C; Leigh-Pemberton R
    Mult Scler; 2020 Nov; 26(13):1729-1739. PubMed ID: 31680631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence.
    Liseno J; Lager B; Miller C; Shankar SL; Mendoza JP; Lewin JB
    Neurol Ther; 2021 Jun; 10(1):349-360. PubMed ID: 33846959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
    Wundes A; Wray S; Gold R; Singer BA; Jasinska E; Ziemssen T; de Seze J; Repovic P; Chen H; Hanna J; Messer J; Miller C; Naismith RT
    Ther Adv Neurol Disord; 2021; 14():1756286421993999. PubMed ID: 33796143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis.
    Lager B; Liseno J; Božin I; England SM; Shankar SL; Mendoza JP; Lewin JB
    Neurol Ther; 2023 Feb; 12(1):145-159. PubMed ID: 36334241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes.
    Swindell WR; Bojanowski K; Chaudhuri RK
    Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data.
    Hauer L; Sellner J
    Drug Des Devel Ther; 2022; 16():3915-3927. PubMed ID: 36388086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera
    Lategan TW; Wang L; Sprague TN; Rousseau FS
    CNS Drugs; 2021 May; 35(5):567-574. PubMed ID: 33797063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decreases ISR activation in DRG neurons.
    Yousuf MS; Moreno MM; Li J; He L; Royer D; Zhang J; Woodall BJ; Grace PM; Price TJ
    bioRxiv; 2023 Dec; ():. PubMed ID: 38187575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.
    Schneider M; Kramer J; Banks A; Moses H
    Mult Scler; 2024 Apr; ():13524585241242027. PubMed ID: 38605496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate.
    Gül S; Ahmed AF; McGraw C
    Cureus; 2023 Jun; 15(6):e40689. PubMed ID: 37485166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
    Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
    Mazzola MA; Raheja R; Regev K; Beynon V; von Glehn F; Paul A; Pierre I; Kivisakk P; Weiner HL; Gandhi R
    Mult Scler; 2019 Jan; 25(1):63-71. PubMed ID: 29106333
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.